Squarepoint’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $226K | Sell |
1,308
-4
| -0.3% | -$742 | ﹤0.01% | 3897 |
|
|
2025
Q4 | $262K | Sell |
1,312
-1,634
| -55% | -$296K | ﹤0.01% | 3695 |
|
|
2025
Q3 | $461K | Buy |
2,946
+1,625
| +123% | +$258K | ﹤0.01% | 3312 |
|
|
2025
Q2 | $200K | Sell |
1,321
-53
| -4% | -$7.07K | ﹤0.01% | 3981 |
|
|
2025
Q1 | $207K | Hold |
1,374
| – | – | ﹤0.01% | 3995 |
|
|
2024
Q4 | $254K | Sell |
1,374
-64,201
| -98% | -$12.4M | ﹤0.01% | 4285 |
|
|
2024
Q3 | $12.9M | Buy |
65,575
+64,179
| +4,597% | +$13.3M | 0.02% | 822 |
|
|
2024
Q2 | $288K | Buy |
1,396
+5
| +0.4% | +$1.13K | ﹤0.01% | 3450 |
|
|
2024
Q1 | $377K | Buy |
1,391
+1
| +0.1% | +$239 | ﹤0.01% | 3239 |
|
|
2023
Q4 | $329K | Sell |
1,390
-15,009
| -92% | -$2.95M | ﹤0.01% | 3292 |
|
|
2023
Q3 | $3.21M | Buy |
16,399
+399
| +2% | +$81.9K | 0.01% | 1470 |
|
|
2023
Q2 | $3.36M | Buy |
+16,000
| New | +$3.18M | 0.01% | 1322 |
|
|
2022
Q3 | – | Sell |
-4,955
| Closed | -$1.06M | – | 3055 |
|
|
2022
Q2 | $1.06M | Sell |
4,955
-57,051
| -92% | -$13.9M | 0.01% | 1566 |
|
|
2022
Q1 | $17.6M | Buy |
62,006
+48,948
| +375% | +$15.1M | 0.08% | 276 |
|
|
2021
Q4 | $4.92M | Buy |
13,058
+12,075
| +1,228% | +$4.69M | 0.01% | 813 |
|
|
2021
Q3 | $406K | Sell |
983
-26,110
| -96% | -$10.8M | ﹤0.01% | 2075 |
|
|
2021
Q2 | $10M | Buy |
27,093
+21,893
| +421% | +$7.31M | 0.04% | 464 |
|
|
2021
Q1 | $1.51M | Sell |
5,200
-43,088
| -89% | -$12M | 0.01% | 1247 |
|
|
2020
Q4 | $12.1M | Buy |
48,288
+38,510
| +394% | +$9.17M | 0.09% | 213 |
|
|
2020
Q3 | $2.21M | Buy |
+9,778
| New | +$2.03M | 0.03% | 614 |
|
|
2020
Q1 | – | Sell |
-25,922
| Closed | -$3.96M | – | 1971 |
|
|
2019
Q4 | $3.96M | Sell |
25,922
-13,784
| -35% | -$1.91M | 0.02% | 586 |
|
|
2019
Q3 | $5.26M | Sell |
39,706
-5,927
| -13% | -$795K | 0.05% | 465 |
|
|
2019
Q2 | $6.47M | Buy |
45,633
+25,755
| +130% | +$3.49M | 0.06% | 358 |
|
|
2019
Q1 | $2.89M | Sell |
19,878
-69,871
| -78% | -$9.18M | 0.03% | 624 |
|
|
2018
Q4 | $10.2M | Buy |
+89,749
| New | +$11.2M | 0.12% | 218 |
|
|
2018
Q2 | – | Sell |
-4,096
| Closed | -$437K | – | 1782 |
|
|
2018
Q1 | $437K | Sell |
4,096
-9,176
| -69% | -$989K | 0.01% | 1140 |
|
|
2017
Q4 | $1.45M | Buy |
13,272
+1,741
| +15% | +$189K | 0.03% | 665 |
|
|
2017
Q3 | $1.25M | Buy |
+11,531
| New | +$1.18M | 0.02% | 657 |
|
|
2017
Q2 | – | Sell |
-15,214
| Closed | -$1.37M | – | 1566 |
|
|
2017
Q1 | $1.37M | Buy |
15,214
+5,452
| +56% | +$463K | 0.04% | 492 |
|
|
2016
Q4 | $744K | Buy |
9,762
+4,912
| +101% | +$373K | 0.03% | 621 |
|
|
2016
Q3 | $404K | Sell |
4,850
-10,975
| -69% | -$920K | 0.03% | 629 |
|
|
2016
Q2 | $1.3M | Sell |
15,825
-13,323
| -46% | -$1.1M | 0.08% | 281 |
|
|
2016
Q1 | $2.21M | Buy |
29,148
+22,424
| +333% | +$1.66M | 0.17% | 151 |
|
|
2015
Q4 | $541K | Buy |
+6,724
| New | +$485K | 0.06% | 496 |
|
|
2015
Q3 | – | Sell |
-6,678
| Closed | -$470K | – | 442 |
|
|
2015
Q2 | $470K | Buy |
+6,678
| New | +$494K | 0.15% | 203 |
|
Other funds holding CRL
VCM
VPM
Squarepoint's CRL Position: Q1 2026 in Review
Squarepoint reduced its Charles River Laboratories (CRL) stake by 0.3% in Q1 2026, selling an estimated $742 and leaving 1,308 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #3897.
Squarepoint first reported a position in CRL in Q2 2015 and has held it in 35 quarters since. The position peaked at $17.6M in Q1 2022. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Squarepoint held 1,308 shares of Charles River Laboratories worth $226K as of Q1 2026.
- Squarepoint sold 4 Charles River Laboratories shares in Q1 2026, an estimated $742.
- Charles River Laboratories made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3897 holding.
- Squarepoint first reported a position in Charles River Laboratories in Q2 2015 and has held it in 35 quarters since.
- Squarepoint's Charles River Laboratories position peaked at $17.6M in Q1 2022.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.